The gentle solution to. Vaginal Atrophy Vaginal Tightening Stress Urinary Incontinence

Similar documents
THE EFFECTIVE, CUTTING-EDGE, HORMONE-FREE LASER TREATMENT FOR VULVOVAGINAL DISEASES

REDISCOVER THE SECRET OF YOUR FEMININITY

THE EFFECTIVE, CUTTING-EDGE, HORMONE-FREE LASER TREATMENT FOR VULVOVAGINAL DISEASES THE NEW TREATMENT CONCEPT BY ASCLEPION BROCHURE NOT FOR THE U.S.A.

FemTouch Treatment for Improving Vulvovaginal Health

Laser Treatment For Vaginal Health

MCL31 Dermablate THE WORLD S MOST SUCCESSFUL ERBIUM:YAG LASER FOR AESTHETIC MEDICINE

FotonaSmooth TM First Non-surgical Laser for Gynecologists

Erbium laser in gynecology

FotonaSmooth. Revolutionary non-surgical laser for vaginal health

THE CLINICAL SOLUTION FOR OPTIMAL FEMININE WELLNESS AT ANY AGE

Energy Based Therapies in Gynecology and Vaginal Health: Update on CO 2

GYNAELASE SPECIALIST CLINICS OF AUSTRALIA. for successful applicants. No need to wait for treatment.

Inclusion Criteria Exclusion Criteria No of Patients included

Compendium of Clinical Studies. Fotona SMOOTH Er:YAG laser treatments in gynecology

FemTouch Clinical Treatment Guide

High Power CO2 Laser + Micro-needle Fractional RF

Evaluation of the Safety and Efficacy of Hybrid Fractional 2940 nm and 1470 nm Lasers for Treatment of Vaginal Tissue: Pilot Study

Evaluation of the Safety and Efficacy of Hybrid Fractional 2940 nm and 1470 nm Lasers for Treatment of Vaginal Tissue: Pilot Study

VAGINAL REJUVENATION

Histology Notes -Part 1: Epithelial Tissues

Non - invasive management and treatment of female stress urinary incontinence with a CO 2

Mona SC-2 Ultra Pulse Co2 Fractional laser system. Beijing Sanhe Beauty S & T Co.,Ltd

MultiPulse PRO - CO 2 Laser -

Laser CO2: una terapia ambulatoriale innovativa nel trattamento delle disfunzioni sessuali femminili

International Journal of Women s Health Care

Vaginal application of fractional CO2 laser (FemiLift) and improvement of female sexual response

The use of laser in urogynaecology

Loss of Bladder Control

MCL 30. MCL 30 Dermablate Fractional Er:YAG (with MICROSPOT EXTENSION SET) EN 1

Tips & Tricks for Usage

The Mona Lisa Touch, a microablative fractionated CO2 laser for vaginal atrophy

APPLICATIONS THAT SELL Part II

BISON. Accento. 755nm Long Pulsed Alexandrite Laser 1064nm Long Pulsed Nd:YAG Laser FOR EXPORT ONLY

Bard: Continence Therapy. Stress Urinary Incontinence. Regaining Control. Restoring Your Lifestyle.

New Treatments for Vaginal Health. Sarah Azad, MD El Camino Women s Medical Group

Tissue: The Living Fabric: Part A

THE GAME CHANGING LASER THERAPY FOR VULVO-VAGINAL HEALTH

Loss of Bladder Control

genitourinary syndrome of menopause Objectives: To evaluate the safety and long-term efficacy of fractional CO2 laser

Introduction ORIGINAL ARTICLE. Pablo González Isaza 1 & Kinga Jaguszewska 2,3 Mariusz Lukaszuk 3

Articoli Scientifici

Embracing New Technologies: Vaginal Laser Therapy. Dean Elterman, MD, MSc, FRCSC Urologic Surgeon University of Toronto

Guide to strengthening the pelvic floor muscles

M & T srl. medical & technology

Intraurethral Erbium:YAG Laser for the Management of Urinary Symptoms of Genitourinary Syndrome of Menopause: A Pilot Study

Using Physiotherapy to Manage Urinary Incontinence in Women

STRUCTURE AND FUNCTION OF THE FEMALE REPRODUCTIVE SYSTEM

Vaginal Er: Smooth Laser (VEL ) Academy Fourth International Focus Meeting

Female Urinary Incontinence: What It Is and What You Can Do About It

Pelvic floor exercises for women. Information for patients Continence Service

By Milena Mincigrucci*, Costante Donati Sarti**, Angelamaria Becorpi***, Massimo Milani, and Gianluca Botta

Pelvic Support Problems

Management of Vaginal Atrophy with Intravaginal Light-Emitting Diodes (LEDs)

Review Article Pelvic Floor Dysfunction, Body Excreta Incontinence and Continence

Preliminary Results after Four Years of MonaLisa Touch Treatments on Subjects with Genitourinary Syndrome of Menopause (GSM).

Summary of the risk management plan (RMP) for Senshio (ospemifene)

Women s and Men s Health Intake Form Comprehensive Physical Therapy Center

Pelvic organ prolapse. Information for patients Continence Service

Tissues. tissue = many cells w/ same structure and function. cell shape aids its function tissue shape aids its function

SMARTXIDE TOUCH INNATE ABILITY. The New Era of Vaginal Rejuvenation

Lecture Overview. Chapter 4 Epithelial Tissues Lecture 9. Introduction to Tissues. Epithelial Tissues. Glandular Epithelium

SMARTXIDE 2 INNATE ABILITY. The New Era of Vaginal Rejuvenation

Pelvic Floor Exercises

Postpartum Complications

Light EVO. Taking care of people, our masterpieces. Multiple Wavelengths for the Highest Challenges in Laser Applications.

FEB-2015 ISSUE. Dr. David Pudukadan

Atrophic Vaginitis. Mimi Clarke Secor CHAPTER 23

Pelvic Floor Muscle Exercises

MENOPAUSE - WHAT TO EXPECT CONCLUSION WEB LINKS

Products, Inc. w/ & w/o Support R#1 R#2 R#3 R#4 R#5. inch mm R#6 R#7 R#8 R#9. inch

Pelvic Floor Exercises

WHITE PAPER SmartXide 2 V 2 LR. MonaLisa Touch Dual Probe Therapy for the Treatment of Lichen Sclerosus and Vaginal Atrophy

How cancer treatments may affect your vagina How a vaginal dilator may help you How to use vaginal dilators Where to buy vaginal dilators

Presentation Product & clinics

Uterine prolapse & Fistulas. Raja Nursing Instructor RN, DCHN, Post RN. BSc.N

Histology: Epithelial tissue

Menopause Symptoms and Management: After Breast Cancer

M u l t i - A p p l i c a t i o n L a s e r S y s t e m

Gynecology Dr. Sallama Lecture 3 Genital Prolapse

diva is a breakthrough laser resurfacing procedure for the improvement of internal vaginal tissue.

CO 2 Laser Treatment Periocular Area. Prof. G.Cannarozzo

MCL31 Dermablate - Er:YAG Laser -

H I S T O L O G Y O F T H E U R I N A R Y S Y S T E M

Incontinence. Anatomy The human body has two kidneys. The kidneys continuously filter the blood and make urine.

MedGyn Gellhorn Pessary. MedGyn Cup Pessary. Products, Inc. Products, Inc.

SMARTXIDE 2 V 2 LR. The New Era of Vaginal Rejuvenation. All it takes is a touch. V 2 LR (Vulvo Vaginal Laser Reshaping) SmartXide 2.

Loss of Bladder Control

CHAPTER 05 Histology: EPITHELIUM

SMARTXIDE TOUCH. The New Era of Vaginal Rejuvenation. All it takes is a touch. V 2 LR (Vulvo Vaginal Laser Reshaping) SmartXide Touch.

TISSUES TYPES. CHAPTER 05 Histology: EPITHELIUM BIO 211: ANATOMY & PHYSIOLOGY I. HISTOLOGY = the study of tissues

The Pelvic Floor Muscles - a Guide for Women

A Simple Solution. to a Common Problem. Find relief from sudden, unplanned urine leakage.

Bio 322 Human Anatomy Objectives for the laboratory exercise Female Reproductive System

Rejuvenating the Vagina A GUIDE TO LABIAPLASTY. Your guide to the female form and treatments for vaginal ageing & rejuvenation

Management of Female Stress Incontinence

Year: Issue 1 Obs/Gyne The silent epidemic: Postmenopausal vaginal atrophy

Stress. incontinence FACTS, ADVICE, AND EXERCISES.

Body Tissues Pearson Education, Inc.

FEMALE URINARY INCONTINENCE: WHAT IT IS AND WHAT YOU CAN DO ABOUT IT

Transcription:

The gentle solution to Vaginal Atrophy Vaginal Tightening Stress Urinary Incontinence

Device specifications Laser: MCL31 Dermablate (Er:YAG), Class 4 Wavelength: Fluence: 2,940 nm Max. 250 J/cm² Pulse duration: 100 1,000 µs Frequency : Modes: Spot size Gyn: 1 20 Hz Gyn C, Gyn W, Ablation, Therm, MicroSpot V-Spot with 90 reflecting gold-coated mirror V-Spot with 360 reflecting gold-coated cone* MicroSpot 13 x 13 mm with variable cover rate* Dimensions: 36 x 60 x 93 cm (W x D x H) Weight: Ca. 75 kg * optional MCL31 IV 100 0116 EN 2

Handpieces specifications Handpieces & V-Spot Handpiece with 90 reflecting gold-coated mirror Optics: V-Spot Handpiece with 360 reflecting gold-coated cone* MicroSpot optic 9 x 9 mm for V-Spot Handpieces MicroSpot Handpiece 13 x 13 mm with variable cover rate* MicroSpot Handpiece* MicroSpot optic for V-Spot V-Spot 90 V-Spot 360 * * optional MCL31 IV 100 0116 EN 3

Advantages in application and technology Application Fast, painless, discreet and easy to use No anesthesia necessary No surgery, minimal downtime Less risk for infection or bleeding Technology Ablative and sub-ablative mode (thermal mode) Most homogeneous beam profile More than 2,000 Er:YAG lasers worldwide Over 15 years experience in Erbium technology MCL31 IV 100 0116 EN 4

Indications Vaginal Atrophy & Tightening Women undergoing menopause often experience a number of symptoms including vaginal dryness, itching, painful intercourse, poor lubrication, decreased libido and poor vaginal muscle elasticity and tone. This condition is also described as Vaginal Atrophy and it follows a reduction in the production of estrogen by the ovaries. It involves the gradual thinning of genital epithelial tissues, vaginal and vulvar mucosa, which reduce in thickness and becomes more fragile, irritable and sensitive to trauma. Another common condition usually associated with natural ageing as well as with vaginal childbirth is the Vaginal Relaxation Syndrome, a loss of the optimum vaginal structure. Most women refer to it complaining a loss of vaginal tightness, which is directly related to the reduction in friction during intercourse and thus to a decrease or loss of sexual gratification. Normal Vagina Enlarged Vagina MCL31 IV 100 0116 EN 5

Indications Vaginal Atrophy & Tightening The wall of the vagina is composed of the following layers: Epithelium: Internal lining of epithelial tissue made up of squamous epithelial cells Lamina propria: Connective tissue that supports the mucosa and connects it with the muscularis Muscularis: Muscle tissue Adventitia: Connective tissue interlaced with elastic fibers, attaches the vagina to surrounding organs The vaginal walls are usually collapsed so that they touch each other. The walls have many folds, which let the vagina enlarge during sexual intercourse and childbirth. Glands near the opening of the vagina secrete mucus that keeps the mucosa moist. Objective of the treatment is to reach the Lamina propria, elastic and rich in collagen that can be stimulated Epithelium Lamina propria Muscularis Adventitia MCL31 IV 100 0116 EN 6

Indications Vaginal Atrophy & Tightening Juliet is a minimally invasive treatment, the goal of which is to restore the original metabolism of connective tissue and improve the state of the mucosa, by stimulating a process of neocollagenesis. This leads to a restoration of the metabolism of connective tissue: the inner mucosa regains elasticity and lubrication, showing improved thickness and softness. This action continues its beneficial effect even after the treatment is finished and, for this reason, many women report further improvements during the first month post-treatment. MCL31 IV 100 0116 EN 7

Indications Stress Urinary Incontinence (Grade 1) Stress Urinary Incontinence (SUI) is a quite widespread disease prevalent in women after their first birth (24% to 29% of women) and in women undergoing menopause because of the reduction estrogen production. Similarly, frequent exercise in high-impact activities can cause athletic incontinence to develop. It is a form of urinary incontinence caused by a loss of support of the urethra, which is usually a consequence of damage to pelvic support structures as a result of childbirth. Women with Stress Urinary Incontinence have an altered connective tissue metabolism, which causes decreased collagen production and which may result in insufficient support of the urogenital tract. The leaking of small amounts of urine during activities which increase abdominal pressure such as coughing, sneezing and lifting weights is a common symptom. Normal ureterovesical Hypermobile ureterovesical junction Q-tip Test Q-tip Test junction MCL31 IV 100 0116 EN 8

Indications Stress Urinary Incontinence (Grade 1) The ligaments of women with SUI have decreased collagen content or qualitative alternations in collagen composition. Women with stress urinary incontinence have an altered connective tissue metabolism causing decreased collagen production, which may result in insufficient support of the urogenital tract. Normal Pelvic floor Muscle Thermal energy from the laser source, especially in moist environments, not only effectively enhances collagen structure but also stimulates neocollagenesis. Weak Pelvic floor Muscle MCL31 IV 100 0116 EN 9

Indications Stress Urinary Incontinence (Grade 1) The Juliet laser treatment leads to a restoration of the metabolism of connective tissue by stimulating new collagen production. This leads Uterus to an improvement in the condition of the mucosa and in the tone of the pelvic muscle, strengthening the vaginal tissue that contributes to Bladder support of the interior tissue and wall. The symptoms of Stress Urinary Incontinence are thus significantly reduced even after the very first treatment. As a result of laser irradiation the intermolecular crosslinks of the triple helix of collagen shorten, which leads to the immediate tightening of collagen fibrils by two-thirds of their length in comparison to the preintervention state. Pelvic floor muscle Urethra Vagina MCL31 IV 100 0116 EN 10

Preparation & Aftercare Inclusion criteria: normal cell cytology (PAP smear), negative urine culture, vaginal canal, introitus and vestibule free of injuries and bleeding. Exclusion criteria: pregnancy, intake of photosensitive drugs, injury or/and active infection in the treatment area, undiagnosed vaginal bleeding and active menstruation. Immediately before the laser treatment: the patie t s vagina (vestibule, introitus and vaginal canal) must be thoroughly washed and the disinfecting solution carefully dried off and removed from the mucosa. After the laser treatment: No special post-op therapy needed. No sexual activities for a period of 72 hours after each of the treatment sessions. With a history of genital herpes for the prevention assign valacyclovir in standard dose for three days before and after the procedure. MCL31 IV 100 0116 EN 11

Parameters & Techniques Phase 1 & 2: Vaginal Atrophy & Stress Urinary Incontinence 1 st Phase: Ablative fractional mode Insert the handpiece in the vagina to the cervix/vaginal vault (7 to 10cm) with the mirror in the upward position Perform the treatment by rotating the handpiece by 45 (line to line) between laser pulses When the of 360 rotation is completed (8 pulses), withdraw the handpiece 1 cm Repeat the process until the 3cm indicator on the handpiece is visible outside of the vagina Mode Gyn C Handpiece V-Spot 90 Fluence 15 35 J/cm 2 * Pulse duration 300 µs Interval Rotation angle 0.5-2 s accordi g user s e perie ce 45 (line to line) 2 nd Phase: Thermal mode Re-insert the handpiece in the vagina to the cervix/vaginal vault (7 to 10cm) with the mirror in the upward position This time, perform the treatment by rotating the handpiece by 22.5 (line and dot) between laser pulses When the of 360 rotation is completed (16 pulses), withdraw the handpiece 0.5cm Repeat the process until the 3cm indicator on the handpiece is visible outside of the vagina MCL31 IV 100 0116 EN 12 Mode Gyn W Handpiece V-Spot 90 Fluence 3 6 J/cm 2 * Pulse duration 1,000 µs Interval Rotation angle 0.5-2 s accordi g user s e perie ce 22.5 (line and dot) * depending on the severity of the condition

Parameters & Techniques Phase 3: Stress Urinary Incontinence (optional) 3 rd Phase: Fractional treatment of vestibule and introitus area Treat the area with 2-3 passes Usually anesthesia is recommended, e.g. Pliaglis from Galderma Mode N25% Handpiece MicroSpot Handpiece Fluence 15 30 J/cm 2 Pulse duration 300 µs Interval 0.5-2 s accordi g user s e perie ce * depending on the severity of the condition MCL31 IV 100 0116 EN 13

Clinical Results MCL31 IV 100 0116 EN 14

Clinical results International studies show the efficacy of the Erbium:YAG technology The Juliet procedure is performed by the MCL31 Dermablate Erbium:YAG laser system. At 2,940 nm, the laser is at the peak for water absorption. And, with the ability for both short and long pulses, studies show that it is more effective than other options. Over 1,000 patients showed excellent improvement with a high level of patient satisfaction (97%) and no adverse effects. Average pelvic floor muscle pressure improved by 60%, vaginal canal shrinkage by 17% and almost 70% of urinary incontinence patients were dry after 120 days (1). In a study of 70 patients, Er:YAG achieved better and more long-lasting results than the CO2 treated ones. Patient discomfort during the treatment, as well as in the post-op period, was significantly higher in the CO 2 group (2). In a study of 37 patients, 100% of patients reported, 6 months after the treatment, improvement in vaginal tightness. 84% reported better sex. In addition, 84% of patients affected by SUI reported significant improvement in the Q-tip test score (3). 1 Saraçoğlu, F.. O er ie of Cos etic G ecolog, LA&HA, Vol. 2013, (1) 2 Gaspar, A. (2013). Evolution of minimally invasive laser treatments for Vaginal Atrophy. LA&HA, Vol. 2013, No 1. 3 Leshunov EV, Martov AG. (2015). Application of laser technologies for treatment of urinary stress incontinence in women of reproductive age. 2015 Jan-Feb;(1):36-40. MCL31 IV 100 0116 EN 15

Clinical results Histological preparation Hematoxylin & Eosin - SETTINGS: Fluence 20 J/cm2 Pulse duration 300 µs MicroSpot Ø 350 µm The sample at day 0 shows an altered epithelium stratification with presence of cornification and superficial areas characterized by very low cellularity. The epithelium appears atrophic and a flattening of the dermal papillae at the dermoepidermal junction can be recognized. 100 µm Day 0 before the treatment Pictures by courtesy of: University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy - Department of Obstetrics and Gynecology, Chief Prof. Rodolfo Milani MCL31 IV 100 0116 EN 16

Clinical results Histological preparation Hematoxylin & Eosin - SETTINGS: Fluence 20 J/cm2 Pulse duration 300 µs MicroSpot Ø 350 µm At day 7 (after one treatment) the pavement epithelium appears well organized, with compact structure and presence of several nuclei, both in the deeper and superficial layers. The depth of the dermal papillae appears moreover increased, showing good tissue vitality. 100 µm Day 7 after 1 treatment Pictures by courtesy of: University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy - Department of Obstetrics and Gynecology, Chief Prof. Rodolfo Milani MCL31 IV 100 0116 EN 17

Clinical results Histological preparation Hematoxylin & Eosin - SETTINGS: Fluence 20 J/cm2 Pulse duration 300 µs MicroSpot Ø 350 µm 100 µm 100 µm Day 0 before the treatment Day 7 after 1 treatment Pictures by courtesy of: University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy - Department of Obstetrics and Gynecology, Chief Prof. Rodolfo Milani MCL31 IV 100 0116 EN 18

Clinical results Two-photon microscopy image Hematoxylin & Eosin - SETTINGS: Fluence 20 J/cm2 Pulse duration 300 µs MicroSpot Ø 350 µm Day 0 before the treatment Split epithelium with few and pyknotic nuclei Day 7 after 1 treatment Multilayered well organized epithelium with presence of nuclei Pictures by courtesy of: University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy - Department of Obstetrics and Gynecology, Chief Prof. Rodolfo Milani MCL31 IV 100 0116 EN 19

Clinical results Polarized light microscopy image Hematoxylin & Eosin - SETTINGS: Fluence 20 J/cm2 Pulse duration 300 µs MicroSpot Ø 350 µm 30 days after 1 treatment Neocollagenogenesis and Angiogenesis processes are still visible; a re-gained uniformity of the tissue is the evidence of efficient tissue regeneration. In addition, the new collagen formation can be recognized through the white stripes visible in the deeper layers. 200 µm Day 30 after 1 treatment Pictures by courtesy of: University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy - Department of Obstetrics and Gynecology, Chief Prof. Rodolfo Milani MCL31 IV 100 0116 EN 20

Clinical results Polarized light microscopy image Hematoxylin & Eosin - SETTINGS: Fluence 20 J/cm2 Pulse duration 300 µs MicroSpot Ø 350 µm 200 µm Day 7 after 1 treatment 200 µm Day 30 after 1 treatment Pictures by courtesy of: University of Milano-Bicocca, San Gerardo Hospital, Monza, Italy - Department of Obstetrics and Gynecology, Chief Prof. Rodolfo Milani MCL31 IV 100 0116 EN 21

Bibliography Female intimate surgery: review of methods and trends Ya.A. Yutskovskaia, E.V. Leshunov, V.D.Trufanov Application of laser technologies for treatment of urinary stress incontinence in women of reproductive age E.V. Leshunov, A.G. Martov (2015) Urologiia, Jan-Feb;(1):36-40. A minimally invasive treatment method for lichen sclerosis E.V. Leshunov, I.V. Kvach, Ya.A. Yutskovskaya Vaginal erbium laser: the second-generation thermotherapy for the genitourinary syndrome of menopause M. Gambacciani, M. Levancini & M. Cervigni (2015), Climacteric, 18:5, 757-763. Genitourinary syndrome of menopause and the use of laser therapy J. Hutchinson-Colas, S. Segal (2015), Maturitas, Dec;82(4):342-5. Rationale and design for the Vaginal Erbium Laser Academy Study (VELAS): an international multicenter observational study on genitourinary syndrome of menopause and stress urinary incontinence M. Gambacciani, M. G. Torelli, L. Martella et al. (2015), Climacteric, 18:sup1, 43-48 Laser Vaginal Tightening (LVT) evaluation of a novel noninvasive laser treatment for vaginal relaxation syndrome E. Jorge, P. Gaviria, A. Jose, L. Lanz (2015), J. LAHA, Vol. 2012, No.1; pp. 59-66. MCL31 IV 100 0116 DE 22

Bibliography First assessment of short-term efficacy of Er:YAG laser treatment on stress urinary incontinence in women: prospective cohort study N. Fisto ić, I. Fisto ić, A. Luka ovič, Š. Fi dri Guštek, I. Sorta Bilajac Turi a & D. Fra ić, Cli acteric, :sup, 7-42. Minimally invasive laser procedure for early stages of stress urinary incontinence (SUI) I. Fisto ić, Š. Fi dri Guštek, N. Fisto ić, J. LAHA, Vol., No. ; pp. -74. Treatment of Vaginal Relaxation Syndrome with an Erbium:YAG Laser Using 90 and 360 Scanning Scopes: A Pilot Study & Short-term Results L. Min Seok (2014), Laser Ther. Jul 1;23(2):129-38. Novel Minimally Invasive VSP Er:YAG Laser Treatments in Gynecology ). Vizi ti, M. Rivera, I. Fisto ić, et al., J. LAHA, Vol., No. ; pp. -58. Erbium laser in gynecology Z. Vizintin, M. Lukac, M. Kazic & M. Tettamanti (2015) Climacteric, 18:sup1, 4-8. MCL31 IV 100 0116 DE 23